TSE:GUD Knight Therapeutics (GUD) Stock Forecast, Price & News C$4.91 +0.03 (+0.61%) (As of 06/6/2023 ET) Add Compare Share Share Today's RangeC$4.82▼C$4.9150-Day RangeC$4.35▼C$4.9652-Week RangeC$4.28▼C$6.20Volume124,835 shsAverage Volume124,759 shsMarket CapitalizationC$534.40 millionP/E RatioN/ADividend YieldN/APrice TargetC$5.97 ProfileProfileAnalyst RatingsChartCompetitorsEarningsInsider TradesHeadlinesSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsInsider TradesHeadlinesSocial Media Knight Therapeutics MarketRank™ ForecastAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside21.5% UpsideC$5.97 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews Sentiment0.00Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.35 out of 5 stars 2.3 Analyst's Opinion Consensus RatingKnight Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of C$5.97, Knight Therapeutics has a forecasted upside of 21.5% from its current price of C$4.91.Amount of Analyst CoverageKnight Therapeutics has only been the subject of 3 research reports in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for GUD. Previous Next 0.0 Dividend Strength Dividend YieldKnight Therapeutics does not currently pay a dividend.Dividend GrowthKnight Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for GUD. Previous Next 1.1 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 2 news articles for Knight Therapeutics this week, compared to 0 articles on an average week.Search Interest1 people have searched for GUD on MarketBeat in the last 30 days. MarketBeat Follows1 people have added Knight Therapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Knight Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders31.23% of the stock of Knight Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 13.91% of the stock of Knight Therapeutics is held by institutions. Previous Next 0.6 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Knight Therapeutics is -35.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Knight Therapeutics is -35.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Growth RatioDue to a projected decrease in earnings for Knight Therapeutics, their PEG ratio cannot be calculated.Price to Book Value per Share RatioKnight Therapeutics has a P/B Ratio of 0.66. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Knight Therapeutics (TSE:GUD) StockKnight Therapeutics Inc., a specialty pharmaceutical company, develops, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices in Canada, Latin America, and internationally. It offers Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib to treat metastatic cholangiocarcinoma; Trelstar for advanced prostate cancer and for pain associated with endometriosis; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic adenocarcinoma; Halaven for metastatic breast cancer and doft tissue sarcoma; and Lenvima for differentiated thyroid cancer, advanced renal cell cancer, and unresectable hepatocellular carcinoma. The company also provides Ladevina for multiple myeloma, myelodysplastic syndrome, mantle cell lymphoma, and follicular lymphoma; Zyvalix for metastatic prostate cancer; Karfib for relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; Rembre for chronic myeloid leukemia; Ambisome and Cresemba for fungal infection; Impavido for leishmaniasis; Exelon for mild to moderately severe dementia; and Ibsrela for the treatment of irritable bowel syndrome with constipation. In addition, it offers Salofalk for ulcerative colitis; Ursofalk to treat biliary cirrhosis; Imvexxy for moderate to severe dyspareunia; Bijuva for moderate to severe vasomotor symptoms associated with menopause in women with intact uteri; Fibridoner to treat idiopathic pulmonary fibrosis; Toliscrin DPI for pseudomonas aeruginosa lung infection in patients with cystic fibrosis; Toliscrin 1-2 for severe acute or resistant chronic infections; and Tobradosa Haler for chronic lung infections. Further, the company finances other life science companies; and invests in life sciences venture capital funds. Knight Therapeutics Inc. was incorporated in 2013 and is headquartered in Montreal, Canada.Read More Receive GUD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Knight Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address GUD Stock News HeadlinesJune 2, 2023 | finance.yahoo.comKnight to Present at the Jefferies 2023 Healthcare Conference in New York CityMay 31, 2023 | theglobeandmail.comClosing Bell: Knight Therapeutics Inc down on Wednesday (GUD)June 6, 2023 | Behind the Markets (Ad)The single greatest medical breakthrough of all time?We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.May 26, 2023 | finance.yahoo.comSamira Sakhia Bought 12% More Shares In Knight TherapeuticsMay 26, 2023 | finance.yahoo.comSamira Sakhia Bought 12% More Shares In Knight Therapeutics \May 23, 2023 | finance.yahoo.comShareholders in Knight Therapeutics (TSE:GUD) are in the red if they invested five years agoMay 8, 2023 | theglobeandmail.comClosing Bell: Knight Therapeutics Inc down on Monday (GUD)May 4, 2023 | finance.yahoo.comNotice of Knight Therapeutics' First Quarter 2023 Results Conference CallJune 6, 2023 | Behind the Markets (Ad)The single greatest medical breakthrough of all time?We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.April 28, 2023 | theglobeandmail.comClosing Bell: Knight Therapeutics Inc down on Friday (GUD)April 18, 2023 | finance.yahoo.comKnight to Present at the 2023 Bloom Burton & Co. Healthcare Investor ConferenceApril 10, 2023 | theglobeandmail.comClosing Bell: Knight Therapeutics Inc up on Monday (GUD)March 28, 2023 | americanbankingnews.comKnight Therapeutics (TSE:GUD) Downgraded by National Bank Financial to "Sector Perform Market Weight"March 27, 2023 | americanbankingnews.comNational Bankshares Trims Knight Therapeutics (TSE:GUD) Target Price to C$6.00March 26, 2023 | americanbankingnews.comKnight Therapeutics (TSE:GUD) Price Target Cut to C$6.50March 25, 2023 | marketwatch.comKnight Therapeutics Inc. ranks on The Globe and Mail's fourth-annual Women Lead Here benchmark of executive gender diversityMarch 23, 2023 | finance.yahoo.comKnight Therapeutics Reports Fourth Quarter and Year-End 2022 ResultsMarch 22, 2023 | americanbankingnews.comKnight Therapeutics (TSE:GUD) Hits New 52-Week Low at $4.92February 28, 2023 | benzinga.comKnight Therapeutics Stock (OTC:KHTRF), Quotes and News SummaryJanuary 27, 2023 | nypost.comSpielberg: ‘Dark Knight’ should’ve been Oscars’ first Best Picture blockbusterJanuary 18, 2023 | msn.comWayne Knight Claims Seinfeld 'Obliterated' His Film CareerNovember 8, 2022 | finance.yahoo.comBullish insiders bet CA$2.9m on Knight Therapeutics Inc. (TSE:GUD)October 11, 2022 | finance.yahoo.comKnight Therapeutics Inc. (TSE:GUD) most popular amongst individual investors who own 57%, insiders hold 20%September 23, 2022 | finance.yahoo.comKnight Therapeutics Inc. places No. 22 on The Globe and Mail's fourth-annual ranking of Canada's Top Growing CompaniesSeptember 1, 2022 | reuters.comKnight Therapeutics IncAugust 15, 2022 | finance.yahoo.comKnight Therapeutics Assumes Commercial Activities and Re-Launches Exelon in BrazilJuly 12, 2022 | finanznachrichten.deBasilea Pharmaceutica AG: Basilea announces Zevtera (ceftobiprole) marketing authorization in BrazilSee More Headlines GUD Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GUD Company Calendar Last Earnings3/23/2023Today6/06/2023Next Earnings (Estimated)8/10/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeTSE Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A SectorMedical Current SymbolTSE:GUD CUSIPN/A CIKN/A Webwww.gud-knight.com Phone514-484-4483FaxN/AEmployees660Year FoundedN/APrice Target and Rating Average Stock Price ForecastC$5.97 High Stock Price ForecastC$6.50 Low Stock Price ForecastC$5.40 Forecasted Upside/Downside+23.3%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)C($0.14) Trailing P/E RatioN/A Forward P/E RatioN/A P/E Growth-1013.5Net IncomeC$-15,020,000.00 Net Margins-4.81% Pretax MarginN/A Return on Equity-1.82% Return on Assets-0.68% Debt Debt-to-Equity Ratio10.09 Current Ratio2.98 Quick Ratio1.79 Sales & Book Value Annual SalesC$312.35 million Price / Sales1.69 Cash FlowC$1.26 per share Price / Cash Flow3.85 Book ValueC$7.44 per share Price / Book0.65Miscellaneous Outstanding Shares108,840,000Free FloatN/AMarket CapC$526.79 million OptionableNot Optionable Beta0.52 Key ExecutivesMr. Jonathan Ross Goodman B.A. (Age 53)BA, L.L.B., LLB, M.B.A., MBA, Exec. Chairman Comp: $455.25kMs. Samira Sakhia BCom (Age 54)CA, CPA, MBA, Pres, CEO & Director Comp: $691.66kMr. Arvind UtchanahChief Financial OfficerMs. Amal Khouri B.Sc.M.B.A., Chief Bus. OfficerMr. Jeff MartensGlobal VP CommercialMr. Leopoldo BosanoVice-Pres of Manufacturing & OperationsMs. Daniela MarinoGlobal VP of Legal & ComplianceMs. Susan Caroline EmblemGlobal VP of HRMs. Jody EngelSr. Director of Bus. Devel.More ExecutivesKey CompetitorsCanopy GrowthTSE:WEEDSupreme CannabisTSE:FIREAurora CannabisTSE:ACBESSA PharmaCVE:EPIICC LabsCVE:ICCView All CompetitorsInsidersSime ArmoyanSold 65,500 sharesTotal: C$380,103.05 ($5.80/share)Sime ArmoyanSold 100,000 sharesTotal: C$580,110.00 ($5.80/share)Samira SakhiaBought 19,455 shares on 6/20/2022Total: C$99,998.70 ($5.14/share)Long Zone Holdings Inc. Bought 18,000 shares on 6/16/2022Total: C$93,240.00 ($5.18/share)View All Insider Transactions GUD Stock - Frequently Asked Questions Should I buy or sell Knight Therapeutics stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Knight Therapeutics in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" GUD shares. View GUD analyst ratings or view top-rated stocks. What is Knight Therapeutics' stock price forecast for 2023? 2 brokerages have issued twelve-month target prices for Knight Therapeutics' stock. Their GUD share price forecasts range from C$5.40 to C$6.50. On average, they predict the company's stock price to reach C$5.97 in the next year. This suggests a possible upside of 23.3% from the stock's current price. View analysts price targets for GUD or view top-rated stocks among Wall Street analysts. How have GUD shares performed in 2023? Knight Therapeutics' stock was trading at C$5.18 on January 1st, 2023. Since then, GUD shares have decreased by 6.6% and is now trading at C$4.84. View the best growth stocks for 2023 here. When is Knight Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023. View our GUD earnings forecast. How were Knight Therapeutics' earnings last quarter? Knight Therapeutics Inc. (TSE:GUD) released its earnings results on Thursday, March, 23rd. The company reported $0.02 earnings per share for the quarter. The firm had revenue of $81.66 million for the quarter, compared to analyst estimates of $62 million. Knight Therapeutics had a negative trailing twelve-month return on equity of 1.82% and a negative net margin of 4.81%. What other stocks do shareholders of Knight Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Knight Therapeutics investors own include Constellation Software (CSU), Bombardier, Inc. Class B (BBD.B), Brookfield Infrastructure Partners (BIP.UN), Enbridge (ENB), Spin Master (TOY), Alimentation Couche-Tard (ATD.B), Chemtrade Logistics Income Fund (CHE.UN), Canadian National Railway (CNR), Dollarama (DOL) and Extendicare (EXE). What is Knight Therapeutics' stock symbol? Knight Therapeutics trades on the Toronto Stock Exchange (TSX) under the ticker symbol "GUD." How do I buy shares of Knight Therapeutics? Shares of GUD stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.Compare Top Brokerages Here. What is Knight Therapeutics' stock price today? One share of GUD stock can currently be purchased for approximately C$4.84. How much money does Knight Therapeutics make? Knight Therapeutics (TSE:GUD) has a market capitalization of C$526.79 million and generates C$312.35 million in revenue each year. The company earns C$-15,020,000.00 in net income (profit) each year or C($0.14) on an earnings per share basis. How many employees does Knight Therapeutics have? The company employs 660 workers across the globe. How can I contact Knight Therapeutics? The official website for the company is www.gud-knight.com. The company can be reached via phone at 514-484-4483. This page (TSE:GUD) was last updated on 6/6/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Knight Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.